Physician profile
James M Mann
NPI 1275582405
$11,365.80
in general payments reported to CMS, 2019-2025
35 companies · $2,733 in 2025
The $2,733 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $52.19 · 2021: $709 · 2022: $2,434 · 2023: $2,349 · 2024: $2,734 · 2025: $2,733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,754 · Education: $62.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,753.63 |
| Education | $62.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,386.83 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,212.19 | 2019-2025 | Xifaxan, Trulance |
| Qol Medical, LLC | $926.19 | 2021-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $577.83 | 2021-2025 | Entyvio, Eohilia |
| Pfizer INC. | $544.68 | 2019-2025 | |
| Janssen Biotech, INC. | $500.42 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $471.91 | 2021-2024 | |
| Genzyme Corporation | $450.82 | 2022-2025 | |
| Ardelyx, INC. | $307.63 | 2023-2025 | Ibsrela |
| Braintree Laboratories, INC. | $278.93 | 2019-2024 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $275.04 | 2022-2024 | Dificid |
| Daiichi Sankyo INC. | $235.73 | 2019-2025 | Injectafer |
| Ferring Pharmaceuticals INC. | $223.36 | 2021-2025 | Rebyota, Clenpiq |
| Fresenius Kabi USA, LLC | $220.45 | 2023-2024 | Idacio |
| Amgen INC. | $219.86 | 2022-2023 | Amjevita, Avsola |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $217.31 | 2023-2025 | Omvoh |
| Celgene Corporation | $211.15 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $155.69 | 2023-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $142.73 | 2021-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $139.14 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $120.86 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $87.27 | 2024-2025 | Vowst, Zenpep |
| Biosense Webster, INC. | $83.15 | 2021-2022 | |
| Celltrion USA INC. | $82.95 | 2024-2025 | Zymfentra, Vegzelma |
| Ipsen Biopharmaceuticals, INC | $58.19 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $56.31 | 2024-2025 | Rezdiffra, Resmetirom |
| Endo Pharmaceuticals INC. | $29.74 | 2019 | |
| Novo Nordisk INC | $24.26 | 2025 | Wegovy |
| Medtronic, INC. | $22.68 | 2025 | Interstim |
| Mylan Institutional INC. | $22.20 | 2023 | Hulio |
| Phathom Pharmaceuticals, INC. | $22.06 | 2025 | Voquezna |
| Biocon Biologics INC | $18.57 | 2024 | Hulio |
| Azurity Pharmaceuticals, INC. | $13.99 | 2025 | Suflave |
| W. L. Gore & Associates, INC. | $12.86 | 2021 | |
| Boston Scientific Corporation | $12.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.